See the DrugPatentWatch profile for Insulin
What is insulin glargine U-300, and how is it different from other glargine insulins?
Insulin glargine U-300 is a long-acting (basal) insulin product made by Sanofi for people with diabetes who need steady background insulin coverage. Compared with insulin glargine U-100 (often sold as Lantus in many markets), U-300 is formulated at a higher concentration (300 units/mL). That formulation changes how the insulin is released from the injection site, which can affect the duration and day-to-day exposure pattern.
What is insulin glargine U-300 used for?
Insulin glargine U-300 is used to improve blood glucose control in people with diabetes who require basal insulin. It is typically used as part of an insulin regimen and may be used with or without mealtime insulin, depending on the patient’s diabetes type and treatment plan.
How is it taken (dosing and administration basics)?
As a long-acting insulin, glargine U-300 is injected once daily (basal coverage). Dosing is individualized based on glucose monitoring and clinician direction. Because it is a concentrated product, it is important that dosing follows the specific prescribing information for U-300 rather than being converted from U-100 using casual unit assumptions.
How do patients usually switch from other basal insulins?
Patients and clinicians generally consider prior insulin dose, glucose trends, hypoglycemia history, and the injection schedule when switching basal insulins. The switch can require close monitoring during the transition period to avoid lows (hypoglycemia) and to reach the intended glucose targets.
What side effects do people ask about?
Common insulin-related adverse effects include hypoglycemia (low blood sugar). Other possible side effects include injection-site reactions and weight gain in some patients. Patients are typically advised to monitor blood glucose regularly and to follow instructions on dose adjustments.
Is insulin glargine U-300 available as a generic or biosimilar?
Whether biosimilars or lower-cost alternatives are available depends on local regulatory approvals and market timing for the specific product and manufacturer. If you’re trying to track competitive and patent-related availability, DrugPatentWatch.com tracks insulin-related intellectual property and can help identify where entry risks or exclusivity issues may be relevant. You can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
Who makes insulin glargine U-300, and what brands exist?
Insulin glargine U-300 is associated with Sanofi’s brand offering in many countries (commonly referred to as Toujeo in the U.S. and other markets, depending on local naming/availability). Availability and naming can vary by country.
Patent and exclusivity: when could competition enter?
Competition timing depends on patent coverage and regulatory exclusivity in each jurisdiction. For readers researching when alternatives (including biosimilars) may become available, DrugPatentWatch.com is a useful starting point because it compiles patent data and links it to the drug product: https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/